

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	HO-P02652US1
-------	---	----	---	------------------------	--------------

Complete If Known

Application Number	10/663,258
Filing Date	September 16, 2003
First Named Inventor	Jose Engelmayr
Art Unit	N/A
Examiner Name	Not Yet Assigned

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CMK	AA	US-5834424	11-10-1998	Valenti et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number-Kind Code ⁴ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	CA	Legrand et al, "The N-terminal Arg2, Arg3, Arg4 of Human Lactoferrin Interact with Sulphated Molecules but Not with the Receptor Present on Jurkat Human Lymphoblastic T-Cells," Biochem J Vol. 327, pp. 841-846 (1997).	
CMK	CB	van Berkel et al, "N-terminal Stretch Arg2, Arg3, and Arg5 of Human Lactoferrin is Essential for Binding to Heparin, Bacterial Lipopolysaccharide, Human Lysozyme and DNA," Biochem J. Vol. 328, pp. 145-151 (1997).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Chih Min Kam/	Date Considered	06/24/2006
--------------------	----------------	-----------------	------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	HO-P02652US1
-------	---	----	---	------------------------	--------------

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CMK	AA	US-5457093	10-10-1995	Cini et al.	
CMK	AB	US-6333311-B1	12-25-2001	Nuijens et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number-Kind Code ⁴ (if known)				
CMK	BA	WO-02100445-A1	12-19-2002	The University of Sydney		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CMK	CA	Yang et al, "Antitumor Activity and Specificity as a Function of Substitutions in the Lipophilic Sector of Helical Lactoferrin-derived Peptide," Journal of Peptide Science 9, 2003, pp. 300-311.	
	CB	Takayama et al, "The Bovine Lactoferrin Region Responsible for Promoting the Collagen Gel Contractile activity of Human Fibroblasts," Biochemical and Biophysical Research Communications 299 (2002), pp 813-817.	
	CC	Yang et al., "Enhanced Antitumor Activity and Selectivity of Lactoferrin-derived peptides," J. Peptide Res. 60, 2002, pp. 187-197.	
	CD	Takayama et al, "Effects of Lactoferrin on Collagen Gel Contractile Activity and Myosin Light Chain Phosphorylation in Human Fibroblasts," FEBS Letter 508, 2001, pp. 111-116.	
	CE	Clarke et al, "Evaluation of Bovine Lactoferrin as a Topical Therapy for Chemotherapy-induced Mucositis in the Golden Syrian Hamster," Oral Oncology 35, 1999, pp. 197-202.	
	CF	Fujihara et al, "Lactoferrin Protects Against UV-B Irradiation-Induced Corneal Epithelial Damage in Rats," Cornea 19(2); 2000, pp. 207-211.	
	CG	Nakajima et al, "Lactoferrin as a Suppressor of Cell Migration of Gastrointestinal Cell Lines," Journal of Cellular Physiology 170, 1997, pp. 101-105.	
	CH	Weinberg, Eugene, "The Therapeutic Potential of Lactoferrin," Expert Opinion Investig. Drugs, 12(5), 2003, pp. 841-851.	
	CI	Cumberbatch et al, "IL-1 B-induced Langerhans' cell Migration and TNF-A production in Human Skin: Regulation by Lactoferrin," Clin Exp. Immunol 132, 2003, pp. 352-359.	
	CJ	He et al, "The Inhibition of Mast Cell Activation by Neutrophil Lactoferrin: Uptake by Mast Cells and Interaction with Tryptase, Chymase and Cathepsin G," Biochemical Pharmacology 65, 2003, pp. 1007-1015.	
▼	CK	Kimber et al, "Lactoferrin: Influence on Langerhans Cells, Epidermal Cytokines, and Cutaneous Inflammation," Biochem Cell Biol. 80, 2002, pp. 103-107.	
	CL	Ward et al, "Lactoferrin and Host Defense," Biochem Cell Biol. 80, 2002, pp. 95-102.	
CMK	CM	Cumberbatch et al, "Regulation of Epidermal Langerhans Cell Migration by Lactoferrin," Immunology 2000, 100, pp. 21-28.	

Examiner Signature	/Chih Min Kam/	Date Considered	06/24/2006
--------------------	----------------	-----------------	------------



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
<p>Application Number</p>		<p>10/663,258</p>			
<p>Filing Date</p>		<p>September 16, 2003</p>			
<p>First Named Inventor</p>		<p>Jose Engelmayer</p>			
<p>Art Unit</p>		<p>N/A</p>			
<p>Examiner Name</p>		<p>Not Yet Assigned</p>			
<p>Sheet</p>	<p>2</p>	<p>of</p>	<p>2</p>	<p>Attorney Docket Number</p>	
<p>HO-P02652US1</p>					

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Chih Min Kam/	Date Considered	06/24/2006
-----------------------	----------------	--------------------	------------



6-16-05

IFW

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/663,258
Sheet	1	of	2	Filing Date	September 16, 2003
				First Named Inventor	Jose Engelmayr
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02652US1

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CMK	AA	US-SN 10/733,621		AGENNIX INCORPORATED	
	AB	US-4,977,137	06-28-1994	AGENNIX INCORPORATED	
	AC	US-SN 10/728,521		AGENNIX INCORPORATED	
	AD	US-5,571,691	11-05-1996	AGENNIX INCORPORATED	
	AE	US-6,399,570	01-04-2002	AGENNIX INCORPORATED	
	AF	US-20040009896	01-15-2004	AGENNIX INCORPORATED	
	AG	US-5,955,316	09-21-1999	AGENNIX INCORPORATED	
	AH	US-20030105006	06-05-2003	AGENNIX INCORPORATED	
	AI	US-6,111,081	08-29-2000	AGENNIX INCORPORATED	
	AJ	US-SN 10/728,275		AGENNIX INCORPORATED	
	AK	US-6,228,614	05-08-2001	AGENNIX INCORPORATED	
	AL	US-SN 10/844,865		AGENNIX INCORPORATED	
	AM	US-5,766,939	06-16-1998	AGENNIX INCORPORATED	
	AN	US-20030190303	10-09-2003	AGENNIX INCORPORATED	
	AO	US-SN 10/732,429		AGENNIX INCORPORATED	
	AP	US-5,571,896	11-05-1996	AGENNIX INCORPORATED	
	AQ	US-20050064546	03-24-2205	AGENNIX INCORPORATED	
	AR	US-20040082504	04-29-2004	AGENNIX INCORPORATED	
	AS	US-6,100,054	08-08-2000	AGENNIX INCORPORATED	
	AT	US-20050075277	04-07-2005	AGENNIX INCORPORATED	
	AU	US-5,198,419	03-30-1993	AGENNIX INCORPORATED	
	AV	US-20040009895	01-15-2004	AGENNIX INCORPORATED	
	AW	US-6,080,559	06-27-2000	AGENNIX INCORPORATED	
	AX	US-SN 10/862,213		AGENNIX INCORPORATED	
V	AY	US-5,849,881	12-15-1998	AGENNIX INCORPORATED	
	AZ	US-6,635,447	10-21-2003	BAYLOR COLLEGE OF MEDICINE	
CMK	AA1	US-5,571,697	11-05-1996	AGENNIX INCORPORATED	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CMK	BA	WO-0203910-A2	01-17-2002		T ²
CMK	BB	JP 07233086A	09-05-1995		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²

Examiner Signature	/Chih Min Kam/	Date Considered	06/24/2006
--------------------	----------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete If Known</i>	
				Application Number	10/663,258
				Filing Date	September 16, 2003
				First Named Inventor	Jose Engelmayr
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	HO-P02652US1

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Chih Min Kam/	Date Considered	06/24/2006
--------------------	----------------	-----------------	------------